Clinical trials: Solid Tumors (Phase 1)
Advanced or Metastatic Solid Tumors
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with berahyaluronidase when administered as a SC injection to participants with advanced solid tumors.
- Trial name
- NCT05017012
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab, Pemetrexed
- Where
- 22 sites in Chile, Hungary and 4 more
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Leptomeningeal Metastasis
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
- Trial name
- NCT06462222
- Testing
- Toripalimab, pemetrexed
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Guangzhou Medical University
Unspecified Adult Solid Tumor, Protocol Specific
Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Mistletoe lectin may slow the growth of cancer cells and be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of mistletoe lectin in treating patients who have advanced solid…
- Trial name
- NCT00006354
- Testing
- mistletoe extract
- Where
- 2 sites in France, Germany
- Volunteers
- 41 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Squamous Cell Carcinoma, Breast Cancer
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma
- Trial name
- NCT02643303
- Testing
- Durvalumab, Tremelimumab, Poly-ICLC
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Ludwig Institute for Cancer Research
Solid Tumor, Cancer
MVX-ONCO-1 in Patients With Solid Tumor
The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who…
- Trial name
- NCT02193503
- Testing
- Treatment
- Where
- Switzerland
- Volunteers
- 34 people
- Sponsor
- Maxivax SA
Advanced Solid Tumor
A Phase I Study of QL1604 for Advanced Solid Tumors
In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.
- Trial name
- NCT05801094
- Testing
- QL1604
- Where
- 2 sites in China
- Volunteers
- 71 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Tumors
A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with…
- Trial name
- NCT00127127
- Testing
- vorinostat
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of oxaliplatin and etoposide in treating young patients with recurrent or refractory solid tumors or lymphomas.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00101205
- Testing
- oxaliplatin, etoposide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Glioma
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an…
- Conditions
- Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT02273739
- Testing
- Enasidenib
- Where
- 12 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Celgene
Solid Tumors
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
The primary objective of this study is: Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of BAY 1436032 in patients with isocitrate dehydrogenase-1 (IDH1)-R132X-mutant advanced…
- Trial name
- NCT02746081
- Testing
- BAY1436032
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 81 people
- Sponsor
- Bayer
Solid Tumor
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors
- Trial name
- NCT07392736
- Testing
- AL8326 tablets, Toripalimab
- Where
- 15 sites in China
- Volunteers
- 228 people
- Sponsor
- Advenchen Laboratories, LLC
Solid Tumours
A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)
This study is open to adults with advanced cancer who have selected types of solid tumours that cannot be surgically removed. People can join the study if they have tried all available treatments and have no other options.
- Trial name
- NCT07827144
- Testing
- BI 4060107
- Where
- 6 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- AIMEDBIO
Unspecified Adult Solid Tumor, Protocol Specific
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006257
- Testing
- paclitaxel, semaxanib
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, NSCLC
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab.
- Conditions
- Ovarian Cancer, NSCLC, ESCC, Solid Tumors
- Trial name
- NCT04939701
- Testing
- ASP0739
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumor (Phase I)
This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.
The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers.
- Trial name
- NCT07797907
- Testing
- BD200
- Volunteers
- 110 people
- Sponsor
- Biolojic Design Ltd.
Advanced or Metastatic Solid Tumors
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
In preclinical study, investigators have demonstrated that the newly developed pan-T booster (harbouring CD40 agonist and one T cell costimulator agonist) co-expressing MSLN CAR T cell possess more powerful antitumor activity…
- Trial name
- NCT05693844
- Testing
- Pan-T booster co-expressing MSLN CAR T cell, Albumin-bound paclitaxel, Cyclophosphamide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chinese PLA General Hospital
Advanced Solid Tumor
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
This is a study to evaluate the safety and tolerability of the study drug HBM1020 which contains two parts. Part 1 will enroll solid tumor participants and Part 2 will enroll renal cell carcinoma (RCC) and colorectal…
- Trial name
- NCT05824663
- Testing
- HBM1020
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Harbour BioMed US, Inc.
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy; locally advanced or metastatic non small cell…
- Trial name
- Protective-1 (NCT03102606)
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 18 sites in United States, China and 2 more
- Volunteers
- 105 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.